SEATTLE, July 05, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ: NSTG ), a provider of life science tools for translational research and molecular diagnostic products, today announced that J. Chad Brown has been appointed Senior Vice President of Sales and Marketing, effective July 5, 2017.
Mr. Brown is a senior healthcare executive with more than 35 years of experience in life science tools and clinical diagnostics. He most recently served as the President and Head of Commercial Operations for North America for Qiagen N.V. From 2007 until 2015, Mr. Brown was with Roche Diagnostics Corporation, where he held a series of commercial leadership positions in the Applied Sciences and Centralized Diagnostics businesses, including as VP of Marketing and VP of Sales for Centralized Diagnostics and as the National Director of Sales for Genomic Systems. Previously, he held sales leadership positions in several medical device and healthcare companies, including Chiron Diagnostics, Rotech Healthcare, Apria Healthcare, and Humana. Mr. Brown earned his BS degree in Health Services Administration from the University of Kentucky.
“NanoString has an exciting portfolio of tools for translational medicine and molecular diagnostics, as well as an enviable pipeline of emerging technologies,” said Chad Brown. “I’m honored to be joining the team and believe that NanoString is exceptionally well-positioned to grow by empowering precision medicine and the rapidly expanding field of immunotherapy.”
“I’m very excited to have Chad join the team at NanoString. Chad has led commercial organizations of substantial scale, and brings a unique combination of experience in both life science tools and diagnostics,” said president and chief executive officer, Brad Gray. “I’d also like to thank Barney Saunders for his many years of leadership, and wish him well in his future endeavors.”
Mr. Brown succeeds Barney Saunders PhD, who served as the company’s commercial leader for almost seven years. Dr. Saunders is expected to stay with NanoString for a three-month transition period before pursuing other professional opportunities.
About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,600 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.
For more information, please visit www.nanostring.com .
NanoString, NanoString Technologies, the NanoString logo, nCounter and Prosigna are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.
Contact: Doug Farrell Vice President, Investor Relations & Corporate Communications dfarrell@nanostring.com Phone: 206-602-1768
